Development of oncolytic adenovirus targetting oral cancer
| Project/Area Number |
26293423
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
北村 哲也 北海道大学, 歯学研究科(研究院), 助教 (00451451)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2016: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Keywords | 口腔がん / 腫瘍溶解アデノウイルス / シスプラチン / アデノウイルス / 腫瘍 / 溶解 / ARE-mRNA / 癌 / ウイルス / トランスレーショナルリサーチ / 腫瘍溶解 / ＡＲＥ－ｍＲＮＡ |
|---|
| Outline of Final Research Achievements |
In this study, we developed an oncolytic adenovirus (AdΔE4), which has mutation in E4 region, targeting oral and other cancer cells. The replication rate of AdΔE4 in cancer cells was higher than that in normal cells. The cytolytic activity of AdΔE4 was also higher in cancer cells. AdΔE4 reduced the volume of tumor formed in nude mice. Furthermore, an oncolytic adenovirus synergistically killed oral cancer cells with cisplatin. These results indicate that AdΔE4 has potential as an oncolytic virus and it suggests the possibility of clinical application.
|
Report
(4 results)
Research Products
(28 results)
-
-
[Journal Article] Habiba U., Hida K., Kitamura T., Yanagawa-Matsuda A., Higashino F., Ito Y.M., Ohiro Y., Totsuka Y. and Shindoh M.2017
Author(s)
Habiba U., Hida K., Kitamura T., Yanagawa-Matsuda A., Higashino F., Ito Y.M., Ohiro Y., Totsuka Y. and Shindoh M.
-
Journal Title
Oncol Lett
Volume: 13
Pages: 321-328
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
